News
The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...
GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening steatohepatitis.
On a quest to expand the eligible patient pool for its fast-growing liver disease drug Rezdiffra, Madrigal Pharmaceuticals ...
1d
Health on MSNRoad to Diagnosis: My Doctors' Focus on My Weight Delayed My MASH Diagnosis for YearsAroosha Sarrafi tells Health her story of getting diagnosed with metabolic dysfunction-associated steatohepatitis (MASH), a ...
Researchers at Peking University have discovered that a filamentous gut fungus, Fusarium foetens, can reverse metabolic ...
Fact checked by Nick Blackmer I was first told that I was at higher risk for fatty liver disease in 2005. I had never heard ...
California biotech NGM Bio is slimming down as the company pivots focus, shedding around 75% of staff, pausing development of ...
Fatty liver disease, also called metabolic dysfunction-associated steatohepatitis (MASH), is a condition where fat ...
AMSTERDAM — A once daily, 50 mg dose of efruxifermin reduced fibrosis at 96 weeks in patients with compensated cirrhosis due ...
18h
MyChesCo on MSNMadrigal Pharmaceuticals Reports Promising Two-Year Data for Rezdiffra in MASH CirrhosisCONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced two-year results from the open-label arm of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results